Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion.
CONCLUSIONS: Dapagliflozin decreased body weight, BMI, waist circumference, total cholesterol, triglycerides, AUC of insulin and total insulin secretion, with a remission of MetS in 58.3%.
PMID: 28001016 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
More News: Cholesterol | Clinical Trials | Dapagliflozin | Endocrinology | Forxiga | Insulin | Medical Ethics | Metabolic Syndrome | Study